Safety Pharmacology Society

Earlier this year, the IQ Consortium's In Vitro Secondary Pharmacology Profiling Working Group published their article, "The state of the art in secondary pharmacology and its impact on the safety of new medicines," in the Nature Reviews Drug Discovery. This publication has recently been honored by the Safety Pharmacology Society as the "Most Impactful Safety Pharmacology Publication of the Year." Congratulations to the authors! Richard Brennan, Steve Jenkinson, Andrew Brown, Annie Delaunois, Berengere Dumotier, Malar Pannirselvam, Mohan Rao, PhD., Lyn Rosenbrier Ribeiro, Friedemann Schmidt, Alicia Sibony, Yoav Timsit, Vicencia Toledo Sales, Duncan Armstrong, Armando Lagrutta, Scott Mittelstadt, Russell Naven, Ravikumar Peri, Sonia Roberts, James Vergis, and Jean-Pierre Valentin #IQpublication #IQconsortium #secondarypharmacology #IQDruSafe

AstraZeneca and the University of Cambridge have 11 funded PhD opportunities which will be available for October 2025 starts. Please check out the link below to see details of the projects that will be available: https://lnkd.in/euEvHHtf Application links will be posted here when available: https://lnkd.in/ewUgmujc Jacqui Hall, FRSBMeghana PatelSteve Rees OBE

👋 The Safety Pharmacology Society Annual Meeting is happening now! #2024SPS. Visit us at booth #209 to discover how ERBC Group can support your drug development from early discovery to clinical stages. Don’t miss our poster presentations: -         𝘐𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 modelling of effects of pimobendan on cardiac output and systemic vascular resistance in beagle dogs by telemetry. – Pascal Champeroux et al. Poster Group A: Tue, Sept 24 (10:45-11:30 AM). -          𝘐𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 modelling of hemodynamic and autonomic effects of a selective α2-adrenoceptor agonist in beagle dogs by telemetry. P – Pascal Champeroux et al. Poster Group A: Tue, Sept 24 (10:45-11:30 AM). -         Adaptation of the Decro Telemetry System for Integrated Safety Pharmacology Endpoints in Dogs. – Raafat Fares et al.Poster Group D: Tue, Sept 24 (8:30-9:15 AM). Additionally, Pascal Champeroux, PhD, ERBC Group Chief Scientific Officer, will present on “Beat-to-Beat In Silico Modeling of Stroke Volume, Vascular Resistance and Cardiac Output from a Standard Telemetry CV Study” during the scientific session today September 24, 2024-12:30 PM-2:00 PM PT. For full details, check the schedule: https://lnkd.in/eyDq3yWp #biotechevent #lifescience #nonclinical #CRO #partnering #drugdevelopment

Is pre-clinical pharmacological safety testing important in your work? Hear how Lumencor instruments can support you at our talk at the Safety Pharmacology Society Annual Meeting! When: Tuesday, September 24, 2:00-3:00pm PST Where: Palm Room 5-6 Subject: "CiPA (Comprehensive in Vitro Proarrythmia) Library Safety Evaluation to Assess Cardiotoxicity Potential Using the VOLTA Scanner" Presented by: Dr. Nick Radio, Global Sales Manager - Strategic Accounts, Lumencor, Inc and Dr. Steve Jenkinson Drug Discovery & Safety Assessment, Metrion Biosciences The evaluation of cardiac safety as a critical parameter in qualifying new drug applications is undertaken to reveal potentially hazardous, unforeseen cardiomyopathy side effects. Accordingly, cardiac safety is a required FDA evaluation for all drug candidates, regardless of class. This seminar focuses on assessing the safety of the Comprehensive in Vitro Proarrhythmia (CiPA) library for determining cardiotoxicity risk by leveraging the automated Lumencor VOLTA Scanner. The CiPA library compounds, with its breadth of nontoxic to toxic effects on human cardiomyocytes, is a well-accepted tool for characterizing sensitivity and selectivity for therapeutic safety. The CiPA library will be tested along three time points: baseline, 1-hour, and 24-hours post-exposure using full 10kHZ VOLTA scanning resolution. Dose-response curves elucidate potency and reproducibility. An analysis of the safety profiles for each compound with respect to cardiotoxicity risk will highlight key parameters such as QTc and QRS interval length. In addition to our talk, we'll host Booth 402. Contact Nick Radio or Brent Samson to schedule a meeting at the show. Learn more about VOLTA: https://hubs.la/Q02NvpTv0 #PharmacologicalSafety #Cardiotoxicity #CiPA #SafetyPharmacology #VOLTAScanner #DrugSafety #2024SPS